KB-1194

MGD007-GPA33-hIgG1

12197

Home » Antibodies » MGD007-GPA33-hIgG1

Background of MGD007-GPA33-hIgG1

GPA33 antigen is uniformly and highly expressed in colorectal cancer, with abundant GPA33 binding sites present in every cell. This suggests that GPA33 may be a potential therapeutic target for colon cancer. The high expression level of GPA33 antigen and the presence of numerous binding sites make it an ideal treatment target. In recent years, research has been ongoing regarding the role of GPA33 antibody in colorectal cancer, and it has been demonstrated that GPA33 antibody can effectively kill GPA33-positive tumor cells. This indicates the potential of GPA33 antibody in treating colon cancer. Further research and development of this potential therapeutic target are expected in clinical settings. Through additional experiments and clinical trials, the efficacy and safety of GPA33 antibody in treating colorectal cancer can be evaluated. If the study results are positive, GPA33 antibody has the potential to become a new treatment method for colon cancer.

Specifications

Catalog Number	KB-1194
Antibody Name	MGD007-GPA33-hIgG1
Isotype	Human IgG1,kappa
Target	GPA33
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Moore P A, Shah K, Yang Y, et al. Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer[J]. Molecular Cancer Therapeutics, 2018, 17(8): 1761-1772.
Wu Z, Guo H F, Xu H, et al. Development of a tetravalent Anti-GPA33/Anti-CD3 bispecific antibody for colorectal cancers[J]. Molecular cancer therapeutics, 2018, 17(10): 2164-2175.
Cheal S M, Xu H, Guo H, et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86 Y-or 177 Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates[J]. European journal of nuclear medicine and molecular imaging, 2016, 43: 925-937.